Effects of Bushen Yiqi Huoxue Decoction in Treatment of Patients with Diminished Ovarian Reserve: A Randomized Controlled Trial.
10.1007/s11655-020-3484-x
- Author:
Jing ZHOU
1
;
Xin-Yao PAN
1
;
Jin LIN
1
;
Qi ZHOU
2
;
Li-Kun LAN
3
;
Jun ZHU
4
;
Ru DUAN
5
;
Lan WANG
1
;
Yan SUN
1
;
Ling WANG
6
Author Information
1. Laboratory for Reproductive Immunology, Hospital & Institute of Obstetrics and Gynecology, Shanghai Medical College, Fudan University, Shanghai, 200000, China.
2. Yangpu Hospital of Traditional Chinese Medicine, Shanghai, 200000, China.
3. Second Affiliated Hospital of Hexi University, Zhangye, Gansu Province, 743000, China.
4. Department of Obstetrics and Gynecology, Wenling People's Hospital, Wenzhou Medical University, Wenzhou, Zhejiang Province, 325000, China.
5. Regulatory Commission Office of the New Cooperative Medical Scheme, Eryuan County, Dali, Yunnan Province, 671000, China.
6. Laboratory for Reproductive Immunology, Hospital & Institute of Obstetrics and Gynecology, Shanghai Medical College, Fudan University, Shanghai, 200000, China. dr.wangling@fudan.edu.cn.
- Publication Type:Randomized Controlled Trial
- Keywords:
Bushen Yiqi Huoxue Decoction;
Chinese medicine;
diminished ovarian reserve;
randomized controlled trial
- MeSH:
Anti-Mullerian Hormone/pharmacology*;
Drugs, Chinese Herbal;
Female;
Follicle Stimulating Hormone;
Humans;
Luteinizing Hormone;
Ovarian Reserve
- From:
Chinese journal of integrative medicine
2022;28(3):195-201
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:To explore the therapeutic effect of Bushen Yiqi Huoxue Decoction BYHD) in patients with diminished ovarian reserve (DOR).
METHODS:A total of 180 patients with DOR diagnosed from December 2013 to December 2014 were equally assigned into progynova and duphaston (E+D) group, Zuogui Pill group and BYHD group with 60 cases in each by computerized randomization. Patients received E+D, Zuogui Pill or BYHD for 12 months, respectively. Follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), anti-Müllerian hormone (AMH), antral follicle count (AFC), ovarian volume, endometrial thickness, and the resistance indices (RIs) of ovarian arteries and uterine arteries were observed before and after treatment.
RESULTS:Nine women (4 from the E+D group, 3 from the Zuogui Pill group, and 2 from the BYHD group) withdrew from the study. After 6 months, Zuogui Pill and BYHD significantly decreased FSH and LH and increased endometrial thickness and AMH (all P<0.01). BYHD also resulted in E2 elevation (P<0.05), ovary enlargement (P<0.05), AFC increase (P<0.01), and RI of ovarian arteries decrease (P<0.05). After 12 months, further improvements were observed in the Zuogui Pill and BYHD groups (all P<0.01), but BYHD showed better outcomes, with lower FSH, larger ovaries and a thicker endometrium compared with the Zuogui Pill group (all P<0.01). However, E+D only significantly increased endometrial thickness (P<0.01) and no significant improvements were observed in the RI of uterine arteries in the three groups.
CONCLUSIONS:BYHD had a favorable therapeutic effect in patients with DOR by rebalancing hormone levels, promoting ovulation, and repairing the thin endometrium. The combination of tonifying Shen (Kidney), benefiting qi and activating blood circulation may be a promising therapeutic strategy for DOR.
